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Abstract 
This study aimed to examine the in-vitro anti-cancer potential of ethyl-p-methoxycinnamate 
(EPMC), the major constituent of Kaempferia galanga (K. galanga) in selected human lung 
adenocarcinoma cells line A549 (p53 wild-type) and H1299 (p53 null). The involvement of 
p53 pathway in the anti-cancer effect of EPMC on selected cells was determined using MTT 
assay and Real-time PCR. The MTT results show that EPMC induces cytotoxicity in a dose- 
dependent manner in A549 cancer cell lines containing the p53 wild-type gene. Meanwhile, 
our RT-PCR results indicate that the apoptotic activity of EPMC does not involve the p53 
pathway. Overall, these results indicate that EPMC compounds of K. galanga stimulates in 
vitro cytotoxic and apoptotic activity unrelated to the p53 pathway. 
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Introduction 
Cancer is a major public health problem 
worldwide. There are many factors that 
may contribute to the development of 
cancer. In many cases, cancer involves 
mutations in protein-encoding genes that 
regulate cell division. Eventually, more 
genes become mutated because the 
genes that normally repair DNA damage 
become themselves mutated and cease to 
function. The amplification of mutations in 
the cell causes further abnormalities in the 
cell and its daughter cells. 
TP53 (tumor suppressor gene p53) 
plays a significant role in protecting cells 
from malignancies. It is well-known that 
p53 suppresses tumor formation and 
protects against DNA damage by inducing 
cell cycle arrest, DNA repair or apoptosis 
(Wang and Sun, 2010). p53 induces cell 
cycle arrest by trans-activating  genes 
such as p21 (CDK-inhibitor 1, cyclin 
dependent kinase) (Chiang et al., 2013). 
Furthermore, p53 initiates apoptosis via 
trans-activating pro-apoptotic proteins 
such as PUMA (p53 upregulated 
modulator of apoptosis) (Bai and Wang, 
2014), BAX (Bcl-2-associated X  protein) 
or FAS (cell surface death receptor) 
(Wang and Sun, 2010). 
However, the p53 is often mutated 
in cancer (Klein and Vassilev, 2004). 
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Evidence suggests that, mutations or 
deletions in the TP53 gene are present in 
nearly 50% of human cancers and 
primarily results in impaired tumor 
suppression function (Wang et al., 2012). 
Loss of p53 functionality leads to the 
proliferation of damaged cells that may 
subsequently transfer the mutations to the 
next generation. It is believed that it is 
through this mechanism that deregulation 
of p53 often leads to the formation of 
tumors (Khoury and Domling, 2012). 
Due to the high occurrence of p53 
mutations in human tumors, this tumor 
suppressor is a key target for novel 
anticancer therapies. Several research 
teams have dealt with the possibility of 
restoring p53 function to treat cancer. 
Many novel molecules have been 
identified so far to restore p53 wild-type 
conformation and thereby recover its 
tumor suppressive function (Hientz et al., 
2017). 
Thus far, a number of studies has 
reported that EPMC, a major constituent 
of volatile oil of K. galanga possesses in 
vitro anti-cancer activities on various 
cancer cell lines such as human colon 
cancer SW620, cervical cancer C33A, 
breast cancer MCF-7 cell lines and oral 
cancer HSC-3 and Ca922 cell lines 
(Amuamuta et al., 2017; Omar et al., 
2017; Omar et al., 2016; Ichwan et al., 
2019). 
Despite these promising results, 
the question of the role of K. galanga in 
the p53 pathway remains unknown. 
Therefore, the objective of this study was 
to determine the in vitro anti-cancer 
potential of EPMC extracted from 
K.galanga against human cancer cell lines 
A549 (lung cancer, p53 wild-type) and 
H1299 (lung cancer, p53 null). The study 
also aims to explore the involvement of 
p53 pathway in anticancer mechanism of 
EPMC extract on human cancer cell lines. 
Materials and Methods 
Cell subculturing and maintenance 
The human lung adenocarcinoma cells 
A549 (wild-type p53) and H1299 (null p53) 
were kindly provided by Prof. Dr. Masa Aki 
Ikeda, Tokyo Medical and Dental 
University, Japan. The cells were grown in 
Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% Penicillin- 
Streptomycin mixture in a humidified 
incubator, 5% CO2 at 37°C. 
MTT assay 
Cell viability was measured by the ability 
of the cells to convert soluble MTT into an 
insoluble formazan crystal. The assay was 
performed according to the protocol 
previously described (Ichwan et al., 2014) 
with slight modifications. Exponentially 
growing cells were subcultured in 96-well 
plates at an initial density of 2x104/ well. 
The cells were exposed to pre-defined 
concentrations of EPMC and doxorubicin 
for 24 hours. 
After 24 hours of incubation, the 
medium was removed and the cells were 
washed with PBS. Cell viability was 
determined by adding 20 µL MTT 3-(4, 5- 
dimetyhlthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide at a concentration of 
5mg/ml (in PBS). Cells were incubated at 
37°C in humidified atmosphere for 4 
hours. The formazan crystals were 
dissolved in 100 µL of dimethylsulfoxide 
(DMSO) for 1 hour. The absorbance was 
measured in a spectrophotometer at a 
wavelength of 570nm (reference: 630 nm). 
Total RNA extraction 
The total RNA Mini Kit was acquired from 
Geneaid (Taiwan). RNA extraction was 
performed following the manufacturer’s 
protocol. 
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Complementary DNA (cDNA) 
preparation 
cDNA synthesis was conducted using 
ReverTra Ace ® qPCR RT Master Mix Kit 
(Toyobo, Japan) based on manufacturer’s 
instructions. A total of 8 µl of solution 
consisting of 4X DN Master Mix, RNA 
template, and nuclease-free water was 
prepared. After incubation for 5 min, 5× 
Master Mix was added to the solution to a 
total of 10 µl of reverse transcription 
solution. Then, the solution was incubated 
at 37 °C for 15min and heated at 98 °C for 
5 min to obtain cDNA. 
Quantitative PCR (qPCR) 
The mRNA expressions of p21 and PUMA 
were determined by qRT-PCR. The RT- 
qPCR was performed using the Quantitect 
SYBR® Green PCR (Qiagen) kit according 
to manufacturers’s instructions. The qRT- 
PCR reaction mixture consists of 2x 
QuantiTect SYBR Green PCR master mix, 
pre-developed gene expression assays, 
primers mix and H2O to a final volume of 
14    µL    were    prepared.    The  relative 
expression level of the mRNA sample was 
normalized by the amount of β-actin, a 
housekeeping gene that was used as 
endogenous control. 
Statistical analysis 
Non-parametric Kruskal-wallis was  used 
to test the significant difference of PUMA 
upregulation between doxorubicin and 
EPMC. 
Results and Discussion 
In brief, we used MTT assay to test 
whether EPMC induced cytotoxicity in 
human lung adenocarcinoma cell lines 
A549 (p53 wild-type) and H1299 (p53 
null). The cells were exposed to graded 
concentrations of EPMC (0-20 µg/mL). 
EPMC was found to decrease cells 
viability in a dose-dependent manner in 
the presence of p53 (Figure 1). However, 
in the absence of p53, EPMC did not 
induce cytotoxicity and cell death (Figure 
2). 
The findings of this study would 
seem to suggest that presence of the p53 
gene is a key factor for sensitivity to 
anticancer agents (El Deiry et al., 2003). 
The H1299 cell line has a recognized p53 
gene deletion in both alleles. Thus, p53- 
null cells succumb to tumorigenesis. 
Unlike p53-null, p53 wild-type have the 
ability to suppress malignant growth of 
transformed cells as well as tumors. 
Therefore, compounds that activate wild- 
type p53 would have an application for the 
treatment of wt-p53 containing human 
cancer. Nevertheless, mutated p53 
confers to the resistance of tumor cells to 
anticancer drugs by inhibiting p53- 
dependent pathway (Volgestein et al., 
2000). 
The cytotoxicity of EPMC on 
human lung cancer cell line was  
compared against doxorubicin, a well- 
known chemotherapeutic agent as a 
positive control. EPMC and doxorubicin 
both induced the cytotoxic activity of p53 
wild-type. 
We next sought to determine 
whether EPMC was involved in the p53 
pathway in A549 and H1299 cell lines 
through the expression of p53 mediated 
target genes (Beckerman et al., 2010). 
The p53 mediated target genes assessed 
in the study were p21 and PUMA. 
As shown in Figure 3, p21 
expression levels were not induced in both 
cancer cell lines after incubation with 
EPMC. However, PUMA expression levels 
in both cancer cell lines increased after 
treatment with EPMC (Figure 4). Non- 
parametric Kruskal-Wallis statistical 
analysis was used to test for significant 
differences in PUMA upregulation upon 
treatment with doxorubicin and EPMC. No 
significant difference in PUMA 
upregulation between doxorubicin and 
EPMC was found. This indicates that 
EPMC is a potent treatment candidate for 
cancer. Furthermore, from the graph 
obtained it showed that the increment was 
more pronounced in A549 (p53 wild-type). 
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In a previous study, PUMA was reported 
to play an important role in benzyl 
isothiocyanate (BITC)-induced apoptosis. 
In the study, treatment with BITC clearly 
increased the level of PUMA in cells with 
wild-type p53 (MCF-7) (Anthony et al., 
2012). 
 
 
 
 
 
 
 
Figure 1. Ethyl-p-methoxycinnamate (EPMC) treatment schedules, EPMC dependent 
cytotoxicity and induced cell death in the presence of p53. 
 
 
 
Figure 2. Ethyl-p-methoxycinnamate (EPMC) does not induce cytotoxicity and cell death in 
dose dependent manner in the absence of p53. 
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Figure 3. The graph shows that mRNA expression was not induced by EPMC incubation in 
both; A549 (p53 wild-type) and H1299 (p53 null) cancer cell line. 
 
 
 
 
Figure 4. RT-PCR analysis revealed that mRNA expression levels were upregulated in both; 
A549 (p53 wild-type) and H1299 (p53 null) cancer cell line. 
 
 
Nevertheless, the upregulation of 
PUMA mRNA expression does not 
indicate the involvement of the p53 
pathway. This is because PUMA can also 
be activated independently and thus plays 
a role in p53-independent apoptosis as in 
the case of the p53 homolog p73, which is 
International Journal of Orofacial and Health Sciences (2020) 1(1) 
33 
 
 
able to engage the PUMA promoter at the 
p53 response elements (Li et al., 2006). 
Thus, in this study EPMC is shown 
to stimulate cytotoxic and apoptotic effects 
on human lung cancer cell lines. However, 
the apoptotic effect of EPMC does not 
involve the p53 pathway. 
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